GAMMA Investing LLC Buys 12,171 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

GAMMA Investing LLC grew its stake in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 5,092.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,410 shares of the company's stock after acquiring an additional 12,171 shares during the period. GAMMA Investing LLC's holdings in Disc Medicine were worth $616,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its holdings in shares of Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after acquiring an additional 266 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Disc Medicine by 8.9% in the 4th quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock valued at $308,000 after acquiring an additional 396 shares in the last quarter. Sterling Capital Management LLC grew its holdings in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after acquiring an additional 503 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Disc Medicine in the 4th quarter valued at about $40,000. Finally, MetLife Investment Management LLC grew its holdings in shares of Disc Medicine by 6.6% in the 4th quarter. MetLife Investment Management LLC now owns 12,132 shares of the company's stock valued at $769,000 after acquiring an additional 755 shares in the last quarter. Institutional investors own 83.70% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Cantor Fitzgerald lifted their price target on Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a report on Tuesday, March 18th. Raymond James Financial started coverage on Disc Medicine in a report on Wednesday, June 11th. They set a "strong-buy" rating and a $89.00 price objective for the company. Scotiabank boosted their price objective on Disc Medicine from $73.00 to $75.00 and gave the stock a "sector outperform" rating in a report on Monday, March 3rd. HC Wainwright restated a "buy" rating and set a $118.00 price objective on shares of Disc Medicine in a report on Tuesday. Finally, TD Cowen started coverage on Disc Medicine in a report on Thursday, February 27th. They set a "buy" rating for the company. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $96.70.

Insider Activity

In other Disc Medicine news, insider William Jacob Savage sold 2,100 shares of the business's stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $50.17, for a total transaction of $105,357.00. Following the completion of the transaction, the insider now directly owns 66,398 shares in the company, valued at $3,331,187.66. The trade was a 3.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mona Ashiya sold 5,738 shares of the business's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $54.11, for a total transaction of $310,483.18. Following the transaction, the director now owns 186,541 shares of the company's stock, valued at approximately $10,093,733.51. This represents a 2.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,511 shares of company stock worth $1,004,277. Corporate insiders own 4.24% of the company's stock.

Disc Medicine Stock Up 3.0%

Shares of NASDAQ IRON traded up $1.52 during midday trading on Friday, reaching $51.61. The company's stock had a trading volume of 413,971 shares, compared to its average volume of 345,690. The company has a quick ratio of 37.65, a current ratio of 37.65 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a fifty-two week low of $30.82 and a fifty-two week high of $68.73. The business's 50 day moving average price is $46.96 and its two-hundred day moving average price is $52.97.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.03). On average, equities analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.